Literature DB >> 22560112

UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis.

Hussein Daoud1, Hamid Suhail, Anna Szuto, William Camu, Francois Salachas, Vincent Meininger, Jean-Pierre Bouchard, Nicolas Dupré, Patrick A Dion, Guy A Rouleau.   

Abstract

Mutations in the UBQLN2 gene, which encodes a member of the ubiquitin-like protein family (ubiquilin-2), have been recently identified in patients with dominant X-linked amyotrophic lateral sclerosis (ALS) and ALS with dementia. We report here the sequencing of the UBQLN2 gene in 590 ALS patients of French and French-Canadian ancestry. We identified two novel missense mutations (p.S155N and p.P189T) in two individuals with sporadic ALS. Bioinformatic analysis predicts that these missense mutations affect the normal protein's function. Importantly, these findings further highlight the importance of the proline residues located in the conserved domains of the ubiquilin-2 protein, suggesting that mutations affecting these residues are particularly relevant to the development of ALS. Our findings further support a causative role of the UBQLN2 gene in the pathogenesis of ALS and suggest that UBQLN2 mutations are rare in the French and French-Canadian population.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22560112     DOI: 10.1016/j.neurobiolaging.2012.03.015

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  16 in total

Review 1.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 2.  Autophagy as a common pathway in amyotrophic lateral sclerosis.

Authors:  Dao K H Nguyen; Ravi Thombre; Jiou Wang
Journal:  Neurosci Lett       Date:  2018-04-04       Impact factor: 3.046

3.  Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines.

Authors:  Joel A Cassel; Allen B Reitz
Journal:  Biochim Biophys Acta       Date:  2013-03-27

Review 4.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

Review 5.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

6.  Identification and biochemical characterization of a novel mutation in DDX11 causing Warsaw breakage syndrome.

Authors:  José-Mario Capo-Chichi; Sanjay Kumar Bharti; Joshua A Sommers; Tony Yammine; Eliane Chouery; Lysanne Patry; Guy A Rouleau; Mark E Samuels; Fadi F Hamdan; Jacques L Michaud; Robert M Brosh; André Mégarbane; Zoha Kibar
Journal:  Hum Mutat       Date:  2012-10-17       Impact factor: 4.878

Review 7.  State of play in amyotrophic lateral sclerosis genetics.

Authors:  Alan E Renton; Adriano Chiò; Bryan J Traynor
Journal:  Nat Neurosci       Date:  2013-12-26       Impact factor: 24.884

Review 8.  Structure, dynamics and functions of UBQLNs: at the crossroads of protein quality control machinery.

Authors:  Tongyin Zheng; Yiran Yang; Carlos A Castañeda
Journal:  Biochem J       Date:  2020-09-30       Impact factor: 3.857

Review 9.  Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis.

Authors:  Shuo-Chien Ling; Magdalini Polymenidou; Don W Cleveland
Journal:  Neuron       Date:  2013-08-07       Impact factor: 17.173

10.  UBQLN2 mutation causing heterogeneous X-linked dominant neurodegeneration.

Authors:  Donald H Harter; Christine E Seidman; Akl C Fahed; Barbara McDonough; Cynthia M Gouvion; Kathy L Newell; Leon S Dure; Martina Bebin; Alexander G Bick; J G Seidman
Journal:  Ann Neurol       Date:  2014-05-09       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.